Technology ID
TAB-4467

A3 Adenosine Receptor Positive Allosteric Modulators

E-Numbers
E-067-2022-1
Lead Inventor
Jacobson, Kenneth (National Institute of Diabetes and Digestive and Kidney Diseases (NIH/NIDDK))
Co-Inventors
Fallot, Lucas (NIDDK)
Ravi, Rama (NIDDK)
Pradhan, Balaram (NIDDK)
Auchampach, John (Medical College of Wisconsin)
Fisher, Courtney (Medical College of Wisconsin)
Applications
Therapeutics
Therapeutic Areas
Oncology
Development Stages
Pre-Clinical (in vitro)
Lead IC
NIDDK
ICs
NIDDK

Selective A3AR agonists are sought as potential agents for treating inflammatory diseases,
chronic pain, cancer and non-alcoholic steatohepatitis (NASH). NIDDK investigators have invented 
new chemical composition as positive allosteric modulators (PAMs) of the A3AR. These chemical 
compounds contain sterically constrained, bridged modifications and cycloalkyl rings of various 
sizes, as well as modifications of the 4-arylamino group. The compounds have added 
three-dimensionality to otherwise flat molecules, which helps distinguish their positive (desired) 
and negative (undesired) pharmacological effects on the action of A3AR agonists. Unlike agonists 
that have side effects, PAM action can be event- and site-specific because adenosine is 
endogenously elevated in response to localized distress
signals within the body.
 

Request More Info

Licensing Contact:
Tong, Betty
tongb@niddk.nih.gov

Patents

  • Patent Cooperation Treaty
    (PCT) PCT/US2023/016769
    Filed on 2023-03-29

Publications

Collaborations

  • Licensing
  • Collaboration

Collaboration Description

  • The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize A3 Adenosine Receptor Positive Allosteric Modulators. For collaboration opportunities, please contact: Dr. Kenneth A. Jacobson at kennethj@niddk.nih.gov
Date Published